Zodlikeproductions
Would you like to react to this message? Create an account in a few clicks or log in to continue.

Biosensors (Profusa, DARPA, Imperial College London)

Post new topic   Reply to topic

Go down

Biosensors (Profusa, DARPA, Imperial College London)  Empty Biosensors (Profusa, DARPA, Imperial College London)

Post by Abacus Fri May 14, 2021 11:09 pm

(July 17, 2016) DARPA invests $7.5 million into Profusa’s tiny tech-packed implantable biosensor
The U.S. military is interested in developing the technology to aid in real-time monitoring of combat soldier health vitals.
Profusa chairman and CEO Ben Hwang said, “Profusa’s vision is to replace a point-in-time chemistry panel that measures multiple biomarkers,
such as oxygen, glucose, lactate, urea, and ions with a biosensor that provides a continuous stream of wireless data,” according to QMed.
Profusa’s bioengineering approach to an implantable biosensor allegedly overcomes the body’s natural reaction
to reject foreign material. The sensors are made of a “smart hydrogel” similar to contact lens material.
digitaltrends.com/cool-tech/darpa-awards-profusa-grant-for-implantable-biosensor/

(March 19, 2018) Injectable Body Sensors Take Personal Chemistry to a Cell Phone Closer to Reality
The team at Profusa is developing a family of tiny biosensors composed of a tissue-like hydrogel, similar to a soft contact lens,
that are painlessly placed under the skin with a single injection. Rather than being isolated from the body,
the biosensors work fully integrated within the body's tissue — without any metal device or electronics,
thereby overcoming the body's attempts to reject it. To date, the injected biosensors have functioned for as long as four years.

Adhered to the skin's surface or held by hand, a separate optical reader is used to read the fluorescent signal from the embedded biosensor.
The reader sends excitation signals through the skin to the biosensor, which then emits fluorescent light in response to the biomolecule present.
prnewswire.com/news-releases/injectable-body-sensors-take-personal-chemistry-to-a-cell-phone-closer-to-reality-300615644.html

(September 30, 2019) Microneedle biosensors accurately detect patient antibiotic levels in real-time
This first-in-human, proof-of-concept study was done at the National Institute of Health Research/ Wellcome Trust Imperial Clinical Research Facility (Imperial College London, London, UK).
Scientists have successfully used microneedle biosensors to accurately detect changes in antibiotic levels in the body, for the first time.
The team believes the technology could change how patients with serious infections
are treated by showing how quickly their bodies 'use up' medications they are given.
The technology has been used for continuous monitoring of blood sugar,
but the Imperial group has, for the first time, shown its potential for use in monitoring changes to drug concentrations.
The research was funded by the NIHR Imperial Biomedical Research Centre and Fondation Mérieux
and supported by the infrastructure of the NIHR Health Protection Research Unit in HCAI and AMR at Imperial and the NIHR Clinical Research Facility at Imperial.
This collaborative work will be advanced further through Imperial's National Centre for Antimicrobial Research and Optimisation (CAMO)
imperial.ac.uk/news/193146/microneedle-biosensors-accurately-detect-patient-antibiotic/

(December 18, 2019) Storing medical information below the skin’s surface
“In areas where paper vaccination cards are often lost or do not exist at all, and electronic databases are unheard of,
this technology could enable the rapid and anonymous detection of patient vaccination history to ensure that every child is vaccinated,”
says Kevin McHugh, a former MIT postdoc who is now an assistant professor of bioengineering at Rice University.
Several years ago, the MIT team set out to devise a method for recording vaccination information
in a way that doesn’t require a centralized database or other infrastructure. To create an “on-patient,” decentralized medical record,
the researchers developed a new type of copper-based quantum dots, which emit light in the near-infrared spectrum.
The researchers designed their dye to be delivered by a microneedle patch
rather than a traditional syringe and needle. Such patches are now being developed to deliver vaccines
for measles, rubella, and other diseases, and the researchers showed that their dye could be easily incorporated into these patches.
Tests using human cadaver skin showed that the quantum-dot patterns could be detected by smartphone cameras
after up to five years of simulated sun exposure. The research was funded by the Bill and Melinda Gates Foundation
and the Koch Institute Support (core) Grant from the National Cancer Institute.
news.mit.edu/2019/storing-vaccine-history-skin-1218

(March 3, 2020) Profusa and Partners Announce Initiation of Study to Measure Early Signs of Influenza Through Biosensor Technology
Profusa, a digital health company that is pioneering the next generation of personalized medicine,
today announced the initiation of a study that will use the Company's minimally invasive injectable biosensor technology,
the Lumee® Oxygen Platform, as a platform to potentially assist in the early detection of influenza outbreaks.
The study, conducted at Imperial College London, will examine how sensors monitoring physiological status,
including the Lumee Oxygen Platform which measures tissue oxygen levels,
provide potential indicators of human response to infection or exposure to disease in healthy volunteers.
The goal of the study is to develop an early identification system to detect not only disease outbreaks,
but biological attacks and pandemics up to three weeks earlier than current methods.
The results of the study are anticipated to be available in 2021.
prnewswire.com/news-releases/profusa-and-partners-announce-initiation-of-study-to-measure-early-signs-of-influenza-through-biosensor-technology-301014961.html

(December 23, 2020) Philips wins $2.8M from DoD for early COVID-19 detection tech
The U.S Defense Department has selected Royal Philips (NYSE:PHG) and BioIntelliSense to receive nearly $2.8 million.
Amsterdam-based Philips (which has its U.S. base in Cambridge, Mass.) was selected by the DoD through a Medical Technology Enterprise Consortium (MTEC)
award to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms, according to a news release.
“Key industry and academic partnerships provide DoD a timely opportunity
to field medical-grade wearables capable of high-frequency physiologic surveillance,”
stated Commander Christopher Steele, Director of the Military Operational Medicine Research Program at USAMRDC.
massdevice.com/philips-wins-2-8m-from-dod-for-early-covid-19-detection/

(January 6, 2021) British Scientists Developing World’s First Covid-19 Vaccine Smart Patch
The patch will use microneedles to both administer the coronavirus vaccine and monitor its efficacy for the patient by tracking the body’s immune response.
The research team plans to develop a prototype by the end of March, in the hope it can be put forward for clinical trials
and ultimately released to the public, as part of the effort to tackle the coronavirus outbreak.
Scientists at Swansea’s IMPACT research centre hope to carry out human clinical studies in partnership with Imperial College London
with the aim of making the device commercially available within three years.
Using polycarbonate or silicon millimetre-long microneedles, the smart patch can penetrate the skin to administer a vaccine.
It can be held in place with a strap or tape for up to 24 hours, during which time it simultaneously measures a patient’s inflammatory response
to the vaccination by monitoring biomarkers in the skin.
unilad.co.uk/news/british-scientists-developing-worlds-first-covid-19-vaccine-smart-patch/

(May 12, 2021) The Smallest-Ever Injectable Chip Hints at a New Cybernetic Medicine
The implant created by the engineers at Columbia is record-breakingly small,
but it's also breaking new ground in simply existing as a wholly functional,
electronic circuit whose total volume is less than 0.1 cubic millimeter.

When incorporated with a low-power temperature sensor to transform the chip into a real-time temperature probe,
the device possesses the ability to monitor body temperature in addition to small variations in temperature
linked to the therapeutic use of ultrasound.In the study, the implant's proof-of-concept was carried out on live mice,
in which it employed ultrasound neurostimulation.

Such tiny chips could also be implanted in the human body, and then communicate measured information and data wirelessly through ultrasound.
As the device stands, it can only measure body temperature, but it could eventually also monitor respiratory function, glucose levels, and blood pressure.
interestingengineering.com/smallest-ever-injectable-chip-hints-at-cybernetic-medicine



Abacus
Guest


Back to top Go down

Biosensors (Profusa, DARPA, Imperial College London)  Empty Re: Biosensors (Profusa, DARPA, Imperial College London)

Post by Abacus Sat May 15, 2021 7:33 pm

(May 13, 2021) Implantable 'living pharmacy' could control body's sleep/wake cycles
A Northwestern University-led team of researchers has signed a cooperative agreement with the Defense Advanced Research Projects Agency (DARPA)
to develop a wireless, fully implantable device that will control the body's circadian clock,
halving the time it takes to recover from disrupted sleep/wake cycles.

Circadian clock research will be led by sleep experts at Northwestern's Center for Sleep and Circadian Biology (CSCB).
Synthetic biologists at Rice University will lead cellular engineering efforts.
And Northwestern engineers will join researchers from Rice and Carnegie Mellon universities and Blackrock Microsystems to develop bioelectronic components.

Combining synthetic biology with bioelectronics, the team will engineer cells
to produce the same peptides that the body makes to regulate sleep cycles,
precisely adjusting timing and dose with bioelectronic controls.
When the engineered cells are exposed to light, they will generate precisely dosed peptide therapies.

Beyond controlling circadian rhythms, the researchers believe this technology could be modified
to release other types of therapies with precise timing and dosing for potentially treating pain and disease.
eurekalert.org/pub_releases/2021-05/nu-ip051321.php

Abacus
Guest


Back to top Go down

Back to top


 
Permissions in this forum:
You can reply to topics in this forum